CHEK1 and osteosarcoma: Overexpression of APOBEC3s was shown to increase responsiveness to targeted ATR (Ataxia Telangiectasia and Rad3-Related) and Chk1/2 (Checkpoint Kinase 1 and 2) inhibitors in acute myeloid leukemia and osteosarcoma cell lines [77,78].